Cerebrovascular Disease. Momentum at the End of the Second Millennium. American Heart Association Monograph Series - Product Image

Cerebrovascular Disease. Momentum at the End of the Second Millennium. American Heart Association Monograph Series

  • ID: 2222065
  • Book
  • Region: United States
  • 455 Pages
  • John Wiley and Sons Ltd
1 of 4
In this book, an international group of investigators from a broad array of clinical and basic disciplines present the ideas and concepts in the foreground of cerebrovascular disease. Included in their discussion are perspectives on topics that continue to guide current investigations, such as white matter injury, newer imaging approaches, delayed neuronal death, and recovery after stroke, as well as continuing disagreements on the value of heparin or MRI endpoints in the management of stroke patients.

Further topics include a proposal for a major multicenter re–study of the utility of extracranial–intracranial bypass surgery in light of additional diagnostic information available through PET scanning; examination of how processes such as apoptosis, inflammation, free radicals, poly (ADP–ribose) polymerase activation, and alterations in glutamate receptor function contribute to the pathogenesis of ischemic brain injury; and finally an exploration of how estrogens or cholesterol–lowering agents might be used therapeutically.

Note: Product cover images may vary from those shown
2 of 4
SECTION I. Extracranial–Intracranial Bypass Surgery: Time for a New Clinical Trial?.

Chapter 1. Overview.

Ralph G. Dacey Jr., MD and William J. Powers, MD.

Chapter 2. Cerebral Hemodynamics and Stroke Risk.

Robert L. Grubb Jr., MD, Colin P. Derdeyn, MD, Susanne Fritsch, RN, William J. Powers, MD.

Chapter 3. Extracranial–Intracranial Bypass: Surgical Considerations.

Marc R. Mayberg, MD.

Chapter 4. Extracranial–Intracranial Surgery for Patients with Proven Hemodynamic Compromise: Is There Sufficient Evidence for a Second–Phase EC/IC Trial?.

Henry J.M. Barnett, MD.

SECTION II. Mediators and Modulators of Ischemic Injury: Hot Topics.

Chapter 5. Poly(ADP–ribose) Polymerase in Ischemia–Reperfusion Injury.

Valina L. Dawson, PhD and Ted M. Dawson, MD, PhD.

Chapter 6. Superoxide Dismutase in Cerebral Ischemia.

Pak H. Chan, PhD.

Chapter 7. Estrogen as Neuroprotectant in Stroke.

Patricia D. Hurn, PhD, Nabil J. Alkaayed, MD, PhD, Barbara J. Crain, MD, PhD, Valina L. Dawson, PhD, Ted M. Dawson, MD, PhD, Allen S. Mandir, MD, PhD, Renata Rusa, MD, Kenji Sampei, MD, Masahiko Sawada, MD, Thomas J.K. Toung, MD, Richard J. Traystman, PhD.

Chapter 8. HMG–coAReductase Inhibitors Reduce Cerebral Infarct Size by Upregulating Endothelial Nitric Oxide Synthase.

Matthias Endres, MD, Ulrich Laufs, MD, James K. Liao, MD and Michael A. Moskowitz, MD.

SECTION III. White Matter Ischemia – Unique Mechanisms of Injury?.

Chapter 9. Ischemic Injury to the Cerebral White Matter: Neuropathology of Human and Experimental Lesions.

Leonardo Pantoni, MD, and Julio H. Garcia, MD (deceased).

Chapter 10. Approaches to the Study of the Cellular and Molecular Pathogenesis of Perinatal White Matter Injury.

Stephen A. Back, MD, PhD.

Chapter 11. White Matter Ischemia: Unique Mechanisms of Injury.

Peter K. Stys, MD.

Chapter 12. CADASIL: What can we Learn about White Matter Stroke?.

Marie–Germaine Bousser, MD, Hugues Chabriat, MD, Anne Joutel, MD and Elizabeth Tournier–Lasserve, MD.

SECTION IV. Inflammation.

Chapter 13. Introduction.

John M. Hallenbeck, MD.

Chapter 14. Infection and Stroke Risk.

Mark Fisher, MD.

Chapter 15. The Extracellular Matrix and Focal Cerebral Ischemia.

Gregory J. del Zoppo, MD.

Chapter 16. Some Principles of the Inflammatory Reaction to Brain Ischemia: Sense and Purpose.

Julie A. Ellison, PhD, Franc C. Barone, PhD and Giora Feuerstein, MD.

Chapter 17. Reperfusion Damage in the Brain.

Ping–An Li, MD, PhD, Tibor Kristian, PhD, Yi–Bing Ouyang, PhD and Bo K. Siesjö, MD, PhD.

Chapter 18. Debate: Heparin Should Be Used to Treat Patients Presenting with Acute Stroke or Stroke–in Evolution: Affirmative Position.

Louis R. Caplan, MD.

Chapter 19. Debate: Antiocoagulation in Acute Ischemic Stroke: Not Indicated.

Roger P. Simon, MD and William J. Powers, MD.

SECTION V. Beyond Diffusion: Imaging Measurements of Cerebral Blood Flow and Metabolism.

Chapter 20. Overview.

Justin A. Zivin, MD, PhD and Marc Fisher, MD.

Chapter 21. Measuring Oxygen Saturation Using Magnetic Resonance Imaging.

E. Mark Haacke, PhD, Weili Lin, MD, Benjamin Lee, MD, Daniel Kido, MD, Chung Y. Hsu, MD and William J. Powers, MD.

Chapter 22. Quantitative Measurement of Regional Blood Flow by Magnetic Resonance with Arterial Spin Tagging.

Alan C. McLaughlin, PhD, Frank Q Ye, PhD, Venkata S. Mattay, MD, Joseph A. Frank, MD, Daniel R. Weinberger, MD.

SECTION VI. Delayed Neuronal Death.

Chapter 23. The GluR2 Hypothesis of Ischemia–Induced Damage: Implications for Neuroprotection and Rescue.

Domenico E. Pellegrini–Giampietro, MD, PhD, Keiji Oguro, MD, PhD, Thoralf Opitz, PhD, Agata Calderone, MD, Michael V.L. Bennett, PhD and R. Suzanne Zukin, PhD.

Chapter 24. Fluorescent Indicator Measurements of Ca2+ Homeostasis in Postischemic CA1 Hippocampal Neurons.

John A. Connor, PhD, Anders C. Greenwood, PhD, Seddigheh Razani–Boroujerdi, PhD, Jeffrey J. Petrozzino, PhD and Rick C.S. Lin, PhD.

Chapter 25. Delayed Neuronal Death: A Perspective and Synthesis.

Myron D. Ginsberg, MD.

SECTION VII. Cortical Reorganization and Post–Acute Stroke Treatment.

Chapter 26. Introduction.

Alexander W. Dromerick, MD and Larry B. Goldstein, MD.

Chapter 27. Functional Remodeling of Motor Cortex after Stroke.

Randolph J. Nudo, PhD, Jeffrey A. Kleim, PhD and Kathleen M. Friel, MD.

Chapter 28. Growth Factors and Stroke Recovery.

Jing Mei Ren, MD, John Markman, MD, and Seth P. Finklestein, MD.

Chapter 29. Activity–Associated Growth Factor Expression and Related Neural Events in ecovery of Function after Brain Injury.

Timothy J. Schallert, PhD, J. Leigh Humm, MA, Sondra Bland, BA, Theresa Jones, PhD, Bryan Kolb, PhD, Jaroslaw Aronowski, PhD and James Grotta, MA.

SECTION VIII. Clinical Treatment Trials.

Chapter 30. Recent Clinical Trials of Neuroprotective Agents and Thrombolytic Therapy for Acute Stroke.

Gregory W. Albers, MD.

Chapter 31. Debate: MRI is a Good Endpoint for Determining the Efficacy of Stroke Treatment Trials: Affirmative position.

Steven J. Warach, MD, PhD.

Chapter 32. Debate: MRI is a Good Endpoint for Determining the Efficacy of Stroke Treatment Trials: Arguments against.

Joseph P. Broderick, MD

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Five Stars ∗∗∗∗∗"This book should be on the shelf of anyone caring for patients with stroke or who are involved in its diagnosis and treatment as it offers the most up–to–date review of the scientific basis for the decision process. The book cannot be compared to any other book in the field as it is the compilation of papers delivered at a conference where a broad range of clinical and basic science topics are covered. This, like all editions of the Princetion Conference Proceedings, should be cherished."

Doody′s Review Service:
Cathy M. Helgason, MD, University of Illinois at Chicago College of Medicine

Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll